Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.

Shamliyan TA, Johnson JR, MacDonald R, Shaukat A, Yuan JM, Kane RL, Wilt TJ.

J Gen Intern Med. 2011 Mar;26(3):326-39. doi: 10.1007/s11606-010-1569-5. Epub 2011 Jan 4. Review.

2.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

3.

Management of chronic hepatitis B.

Wilt TJ, Shamliyan T, Shaukat A, Taylor BC, MacDonald R, Yuan JM, Johnson JR, Tacklind J, Rutks I, Kane RL.

Evid Rep Technol Assess (Full Rep). 2008 Oct;(174):1-671. Review.

4.

Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.

Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, Price A.

Health Technol Assess. 2009 Jul;13(35):1-172, iii. doi: 10.3310/hta13350. Review.

5.

A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.

Takeda A, Jones J, Shepherd J, Davidson P, Price A.

J Viral Hepat. 2007 Feb;14(2):75-88. Review.

PMID:
17244247
6.

Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference.

Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, Tacklind J, Rutks I, Kane RL, Wilt TJ.

Ann Intern Med. 2009 Jan 20;150(2):111-24. Epub 2009 Jan 5. Review.

PMID:
19124812
7.
8.

[Interferon in hepatitis B].

García Buey L, González Mateos F, Moreno Otero R.

Enferm Infecc Microbiol Clin. 2008 May;26 Suppl 7:19-31. Review. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2008 Dec;26(10):675.

PMID:
19100228
9.

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.

Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005441. Review.

PMID:
24585509
10.

Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.

Hauser G, Awad T, Thorlund K, Štimac D, Mabrouk M, Gluud C.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005642. doi: 10.1002/14651858.CD005642.pub3. Review.

PMID:
24585451
11.

Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.

Buster EH, Schalm SW, Janssen HL.

Best Pract Res Clin Gastroenterol. 2008;22(6):1093-108. doi: 10.1016/j.bpg.2008.11.007. Review.

PMID:
19187869
12.

Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis.

Kim V, Abreu RM, Nakagawa DM, Baldassare RM, Carrilho FJ, Ono SK.

J Viral Hepat. 2016 Mar;23(3):154-69. doi: 10.1111/jvh.12418. Epub 2015 May 13. Review.

PMID:
25967226
13.

Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B.

Keating GM.

Drugs. 2009;69(18):2633-60. doi: 10.2165/11203660-000000000-00000. Review.

PMID:
19943712
14.

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.

Jones J, Colquitt J, Shepherd J, Harris P, Cooper K.

Health Technol Assess. 2010 May;14 Suppl 1:23-9. doi: 10.3310/hta14Suppl1/04. Review.

15.
16.

Entecavir for the treatment of chronic hepatitis B infection.

Shepherd J, Gospodarevskaya E, Frampton G, Cooper K.

Health Technol Assess. 2009 Oct;13 Suppl 3:31-6. doi: 10.3310/hta13suppl3/05. Review.

17.

Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.

Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, Pham B, Ungar WJ, Einarson TR, Heathcote EJ, Krahn M.

Gastroenterology. 2010 Oct;139(4):1218-29. doi: 10.1053/j.gastro.2010.06.042. Epub 2010 Jun 20. Review.

PMID:
20600036
18.

A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.

Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P.

Clin Ther. 2010 Aug;32(9):1565-77. doi: 10.1016/j.clinthera.2010.08.009. Review.

PMID:
20974315
19.

Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection.

Xia Y, Luo H, Liu JP, Gluud C.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009004. doi: 10.1002/14651858.CD009004.pub2. Review.

PMID:
23633363
20.

The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.

Hartwell D, Cooper K, Frampton GK, Baxter L, Loveman E.

Health Technol Assess. 2014 Oct;18(65):i-xxii, 1-202. doi: 10.3310/hta18650. Review.

Supplemental Content

Support Center